<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Liedtke, Alina G.</dc:creator>
  <dc:creator>Lava, Sebastiano A. G.</dc:creator>
  <dc:creator>Milani, Gregorio P.</dc:creator>
  <dc:creator>Agostoni, Carlo</dc:creator>
  <dc:creator>Gilardi, Viola</dc:creator>
  <dc:creator>Bianchetti, Mario G.</dc:creator>
  <dc:creator>Treglia, Giorgio</dc:creator>
  <dc:creator>Faré, Pietro B.</dc:creator>
  <dc:date>2019-12-27</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Selective ß2-agonists have been imputed as potential cause of l-hyperlactatemia since the 1970s. To document the prevalence of hyperlactatemia associated with selective ß2-agonists and to investigate the  predisposing factors, we searched for published articles until April 2019 pertaining to the interplay of administration of selective ß2-agonists and circulating l-lactic acid in the Excerpta Medica, Web of Science,  and the U.S. National Library of Medicine databases. Out of the 1834 initially retrieved records, 56 articles were included: 42 papers reporting individual cases, 2 observational studies, and 12 clinical trials. Forty- seven individual patients receiving a selective ß2-agonist were found to have l-lactatemia ≥5.0 mmol/L, which decreased by ≥3.0 mmol/L or to ≤2.5 mmol/L after discontinuing (N = 24), reducing (N = 17) or  without modifying the dosage of the selective ß2-agonist (N = 6). Clinical trials found that l-lactic acid significantly increased in healthy volunteers administered a ß2-agonist. l-lactatemia ≥5.0 mmol/L was  observed in 103 (24%) out of 426 patients with asthma or preterm labor managed with a selective ß2-agonist and was more common in patients with asthma (30%) than in premature labor (5.9%). A significant  relationship was also noted between l-lactate level and intravenous albuterol dose or its circulating level. In conclusion, relevant l-hyperlactatemia is common on high dose treatment with a selective ß2-agonist.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/319144</dc:identifier>
  <dc:identifier>https://n2t.net/ark:/12658/srd1319144</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319144/files/Liedtke_JCM_2019.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/jcm9010071</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319144</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Journal of clinical medicine. - 2020, vol. 9, no. 1, p. 71</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Acidosis</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Kussmaul breathing</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Lactate</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Lactic acid</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">ß2-adrenoceptor agonist</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns6="xml" ns6:lang="en">Selective ß2-adrenoceptor agonists and relevant hyperlactatemia : systematic review and meta-analysis</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
